June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Hurdles and advantages in an example of regenerative medicine
Author Affiliations & Notes
  • Graziella Pellegrini
    University of Modena and Reggio Emilia, Centre for Regenerative Medicine Stefano Ferrari, Modena, Italy
  • Footnotes
    Commercial Relationships Graziella Pellegrini, HOLOSTEM TERAPIE AVANZATE SRL (E), JAPAN TISSUE ENGINEERING CO. LTD ( (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3476. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Graziella Pellegrini; Hurdles and advantages in an example of regenerative medicine. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3476. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Recent breakthroughs in regenerative medicine have generated enthusiasm and many efforts to explore new therapeutic potentials of both somatic and pluripotent stem cells. About 30 years passed since a discovery of a method of producing a great number of human epidermal keratinocytes by cultivation from a small skin biopsy. Many possibilities are now envisaged for therapeutic application of different cultured cell types. The purpose of this work is to understand whether regenerative medicine will offer, in the near future, new therapies and an unimpeded distribution by academies and by the new pharmaceutical industry throughout the world.

Methods: An extensive and experimental work was done to test whether a stem cell therapy can be classified under the European regularory framework, designed for chemical manufacturing in the last century. Reclassification of biological parameters in a EU GMP environment has been presented.

Results: Ocular burns cause depletion of limbal stem cells, which leads to corneal opacification and visual loss. Most of available treatments are palliative and focused on the relief of the devastating clinical picture. Several studies focused on recent developments in cell-based therapy of limbal stem cell deficiency. After 15 years follow-up, all findings provide data for improvement and support aimed to a standardization of the cure for this disabling disease.

Conclusions: Living cell-based products present many challenges in today's highly regulated healthcare environment; however, analysis of all experimental conditions and deep knowledge of the process can provide strong support to translation of biology in a regulatory environment.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.